NovoCure Limited financials
$15.95−0.25%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M | $535.0M | $494.4M | $351.3M | $248.1M | $177.0M | $82.9M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M | $420.2M | $387.9M | $262.7M | $168.0M | $121.4M | $36.6M |
| Gross margin | 74.5% | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% | 74.8% | 67.7% | 68.6% | 44.2% |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M | -$44.3M | $30.4M | -$914.0K | -$33.7M | -$39.3M | -$115.3M |
| Net income | -$136.2M | -$168.6M | -$207.0M | -$92.5M | -$58.4M | $19.8M | -$7.2M | -$63.6M | -$61.7M | -$131.8M |
| Net margin | −20.8% | −27.9% | −40.6% | −17.2% | −10.9% | 4.0% | −2.1% | −25.6% | −34.8% | −159.1% |
| Diluted EPS | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.18 | $-0.07 | $-0.69 | $-0.70 | $-1.54 |
| EBITDA | -$139.2M | -$159.3M | -$221.9M | -$78.9M | -$34.1M | $39.6M | $7.5M | -$24.7M | -$31.7M | -$109.7M |
| Operating cash flow | -$49.0M | -$26.4M | -$73.3M | $30.8M | $82.8M | $99.1M | $26.6M | -$1.9M | -$33.1M | -$107.6M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M | $58.6M | $84.2M | $16.1M | -$8.6M | -$40.5M | -$125.3M |
| Diluted shares | 111.5M | 107.8M | 106.4M | 104.7M | 103.4M | 108.9M | 97.2M | 91.8M | 88.5M | 85.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $93.5M | $163.8M | $240.8M | $115.3M | $208.8M | $234.7M |
| Short-term investments | $354.1M | $796.1M | $669.8M | $854.1M | $728.9M | $607.9M |
| Total debt | $195.0M | $655.5M | $568.8M | $565.5M | $562.2M | $429.9M |
| Total assets | $804.3M | $1.24B | $1.15B | $1.19B | $1.14B | $1.05B |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M | $575.5M |
| Shareholders' equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M | $476.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology